SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given the increased risk of death from cirrhosis-related complications in patients ...

Berlin: Bayer has announced the initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational ...

in patients with advanced HBV-related hepatocellular carcinoma (HCC). These data were presented at the European Association for the Study of the Liver (EASL) Congress 2025. The results ...

Bayer begins phase I study targeting GPC3 with actinium-225 radiopharmaceutical in patients with advanced hepatocellular carcinoma: Berlin Wednesday, April 30, 2025, 12:00 Hrs [IS ...

in patients with advanced hepatocellular carcinoma (HCC). Oncofetal protein GPC3 is a membrane-associated proteoglycan which is overexpressed in 70-75% of HCC lesions making it an attractive ...

General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...